Novartis Oncology Strategy: Focus On The Microenvironment
Executive Summary
As ASCO approaches, Novartis tries to highlight its oncology offerings, despite a very early immuno-oncology pipeline.
You may also be interested in...
Lilly's Abemaciclib Hit Leaves It Down But Not Out
Continuation of Phase III MONARCH 2 study, with no early termination for efficacy, may mean a delay in filing and a tougher competitive outlook against Pfizer's Ibrance and Novartis' ribociclib.
Does Novartis Need A Big Immuno-Oncology Deal? Jimenez Says No
The oncology player missed out on the first round of immune checkpoint inhibition and now some investors are wondering if the pharma needs to buy a rival to catch up. During the company’s second quarter sales call CEO Jimenez insisted Novartis has the internal expertise to execute.
Novartis Rejiggers Pharma To Favor Oncology
The Swiss pharma changes the leadership structure of its pharmaceutical division in an effort to emphasize oncology; AstraZeneca's Paul Hudson takes over the non-oncology pharma group as David Epstein leaves the company.